Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Liabilities

Latest as of June 2025: CN¥1.29 Billion CNY ≈ $189.13 Million USD

Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has total liabilities worth CN¥1.29 Billion CNY (≈ $189.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) cash conversion ratio to assess how effectively this company generates cash.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Liabilities Trend (2019–2024)

This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt to evaluate the company's liquid asset resilience ratio.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Liabilities

The table below lists competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ranked by their total liabilities.

Company	Country	Total Liabilities
Shenzhen Centralcon Investment Holding Co Ltd SHE:000042	China	CN¥31.48 Billion
Procter & Gamble Health Limited NSE:PGHL	India	Rs2.75 Billion
Shandong Fengyuan Chemical Co Ltd SHE:002805	China	CN¥2.86 Billion
Nesco Limited NSE:NESCO	India	Rs5.54 Billion
Harbin Xinguang Optic Electronics SHG:688011	China	CN¥156.89 Million
Shenzhen Sosen Electronics Co.Ltd. SHE:301002	China	CN¥662.61 Million
Mingchen Health Co Ltd Class A SHE:002919	China	CN¥350.70 Million

Liability Composition Analysis (2019–2024)

This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301096 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.33	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2024)

The table below shows the annual total liabilities of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.14 Billion ≈ $167.08 Million	+15.92%
2023-12-31	CN¥984.97 Million ≈ $144.13 Million	+120.13%
2022-12-31	CN¥447.45 Million ≈ $65.48 Million	-26.30%
2021-12-31	CN¥607.10 Million ≈ $88.84 Million	+90.19%
2020-12-31	CN¥319.20 Million ≈ $46.71 Million	+219.55%
2019-12-31	CN¥99.89 Million ≈ $14.62 Million	--

About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

SHE:301096 China Drug Manufacturers - General

Market Cap

$936.00 Million

CN¥6.40 Billion CNY

Market Cap Rank

#9390 Global

#2571 in China

Share Price

CN¥58.56

Change (1 day)

+4.66%

52-Week Range

CN¥34.37 - CN¥68.99

All Time High

CN¥98.58